Riximyo (rituximab)

pCPA File Number: 21188

Negotiation Status:

Concluded with an LOI

Indication(s):

Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma

Sponsor/Manufacturer:

Sandoz Canada Inc.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2020-04-24

Negotiation Process Concluded:

2020-06-19